• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

P物质通过不同的受体刺激和抑制肠道蠕动。

Substance P stimulates and inhibits intestinal peristalsis via distinct receptors.

作者信息

Holzer P, Schluet W, Maggi C A

机构信息

University Department of Experimental and Clinical Pharmacology, Graz, Austria.

出版信息

J Pharmacol Exp Ther. 1995 Jul;274(1):322-8.

PMID:7542335
Abstract

The tachykinins substance P (SP) and neurokinin A participate in the neural control of intestinal peristalsis. This study aimed at elucidating the types of tachykinin receptors involved in SP's ability first to stimulate and then to inhibit propulsive activity. Peristalsis in the guinea pig isolated ileum was triggered by fluid-induced distension of the intestinal wall. Unlike SP, the neurokinin (NK)-1 receptor-selective agonist SP methyl ester (1-100 nM) failed to facilitate peristalsis but caused a delayed inhibition of peristaltic activity. In contrast, the NK-2 receptor-selective agonist [beta-Ala8]-NKA-(4-10) (BANKA, 1-100 nM) stimulated, but did not inhibit, peristalsis. The NK-3 receptor-selective agonist succinyl-[Asp6,N-MePhe8]-substance P-(6-11) (SENKTIDE, 0.1-10 nM) was most potent in facilitating propulsive activity, and only with 10 nM SENKTIDE was a delayed inhibition of peristalsis seen. The receptors responsible for the tachykinin-evoked stimulation and inhibition of peristaltic activity were further characterized by use of the NK-1 receptor-selective antagonist (+)-(2S,3S)-3-(2-methoxybenzylamino)-2-phenylpiperidine (CP-99,994, 300 nM) and the NK-2 selective antagonist (-)-N-methyl-N[4-acetylamino-4-phenyl-piperidino-2 (3,4 dichlorophenyl)butyl]-benzamide (SR-48,968, 100 nM). CP-99,994 antagonized the inhibitory effects of SP (100 nM) and SP methyl ester (100 nM) on peristalsis but did not alter the facilitation of propulsive motility brought about by SP or BANKA (100 nM). Conversely, SR-48,968 (100 nM) suppressed the ability of SP and BANKA to stimulate persitaltic activity but did not attenuate the inhibitory motor effects of SP and SP methyl ester.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

速激肽P物质(SP)和神经激肽A参与肠道蠕动的神经控制。本研究旨在阐明参与SP先刺激然后抑制推进活动能力的速激肽受体类型。豚鼠离体回肠中的蠕动由液体诱导的肠壁扩张引发。与SP不同,神经激肽(NK)-1受体选择性激动剂SP甲酯(1 - 100 nM)未能促进蠕动,但导致蠕动活动延迟抑制。相反,NK - 2受体选择性激动剂[β - Ala8]-NKA -(4 - 10)(BANKA,1 - 100 nM)刺激但不抑制蠕动。NK - 3受体选择性激动剂琥珀酰 - [Asp6,N - MePhe8]-P物质 -(6 - 11)(SENKTIDE,0.1 - 10 nM)在促进推进活动方面最有效,仅在10 nM SENKTIDE时可见蠕动的延迟抑制。通过使用NK - 1受体选择性拮抗剂(+) - (2S,3S) - 3 - (2 - 甲氧基苄基氨基) - 2 - 苯基哌啶(CP - 99,994,300 nM)和NK - 2选择性拮抗剂( - ) - N - 甲基 - N[4 - 乙酰氨基 - 4 - 苯基 - 哌啶基 - 2(3,4 - 二氯苯基)丁基] - 苯甲酰胺(SR - 48,968,100 nM)进一步表征了负责速激肽诱发的蠕动活动刺激和抑制的受体。CP - 99,994拮抗SP(100 nM)和SP甲酯(100 nM)对蠕动的抑制作用,但不改变SP或BANKA(100 nM)引起的推进运动促进作用。相反,SR - 48,968(100 nM)抑制SP和BANKA刺激蠕动活动的能力,但不减弱SP和SP甲酯的抑制性运动效应。(摘要截短于250字)

相似文献

1
Substance P stimulates and inhibits intestinal peristalsis via distinct receptors.P物质通过不同的受体刺激和抑制肠道蠕动。
J Pharmacol Exp Ther. 1995 Jul;274(1):322-8.
2
Differential activation of the epithelial and smooth muscle NK1 receptors by synthetic tachykinin agonists in guinea-pig trachea.豚鼠气管中合成速激肽激动剂对上皮和平滑肌NK1受体的差异性激活
Br J Pharmacol. 1997 Jun;121(4):773-81. doi: 10.1038/sj.bjp.0701188.
3
Characterization of tachykinin receptors in the uterus of the oestrogen-primed rat.雌激素预处理大鼠子宫中速激肽受体的特性研究
Br J Pharmacol. 1998 Jan;123(2):259-68. doi: 10.1038/sj.bjp.0701613.
4
Ava[L-Pro9,N-MeLeu10] substance P(7-11) (GR 73632) and Sar9, Met(O2)11 increase distention-induced peristalsis through activation of neurokinin-1 receptors on smooth muscle and interstitial cells of cajal.阿伐[L-脯氨酸9,N-甲基亮氨酸10]P物质(7-11)(GR 73632)和Sar9,Met(O2)11通过激活平滑肌和 Cajal 间质细胞上的神经激肽-1 受体来增强扩张诱导的蠕动。
J Pharmacol Exp Ther. 2006 Apr;317(1):439-45. doi: 10.1124/jpet.105.094920. Epub 2005 Dec 5.
5
Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.ZD6021的药理学特性:一种新型的、口服活性速激肽受体拮抗剂。
J Pharmacol Exp Ther. 2001 Jul;298(1):307-15.
6
Characterization of receptors mediating contraction induced by tachykinins in the guinea-pig isolated common bile duct.豚鼠离体胆总管中速激肽介导收缩的受体特性研究
Br J Pharmacol. 1997 Dec;122(8):1633-8. doi: 10.1038/sj.bjp.0701560.
7
Roles of substance P receptors in human colon circular muscle: alterations in diverticular disease.P物质受体在人结肠环行肌中的作用:憩室病中的改变
J Pharmacol Exp Ther. 2002 Aug;302(2):627-35. doi: 10.1124/jpet.102.034702.
8
The inhibitory modulation of guinea-pig intestinal peristalsis caused by capsaicin involves calcitonin gene-related peptide and nitric oxide.辣椒素引起的豚鼠肠道蠕动抑制性调节涉及降钙素基因相关肽和一氧化氮。
Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):102-9. doi: 10.1007/BF00168922.
9
Pharmacological examination of the neurokinin-1 receptor mediating relaxation of human intralobar pulmonary artery.介导人叶内肺动脉舒张的神经激肽-1受体的药理学研究
J Pharmacol Exp Ther. 2000 Jan;292(1):319-25.
10
In vitro characterization of tachykinin NK2-receptors modulating motor responses of human colonic muscle strips.速激肽NK2受体对人结肠肌条运动反应调节作用的体外特性研究
Br J Pharmacol. 1998 Jul;124(6):1321-7. doi: 10.1038/sj.bjp.0701960.

引用本文的文献

1
Human resident gut microbe regulates colonic neuronal innervation and neurogenic function.人体常驻肠道微生物调节结肠神经元支配和神经发生功能。
Gut Microbes. 2020 Nov 1;11(6):1745-1757. doi: 10.1080/19490976.2020.1766936. Epub 2020 Jun 9.
2
Ginsenoside Re protects methamphetamine-induced dopaminergic neurotoxicity in mice via upregulation of dynorphin-mediated κ-opioid receptor and downregulation of substance P-mediated neurokinin 1 receptor.人参皂苷 Re 通过上调强啡肽介导的 κ 阿片受体和下调 P 物质介导的神经激肽 1 受体来保护小鼠的甲基苯丙胺诱导的多巴胺能神经毒性。
J Neuroinflammation. 2018 Feb 21;15(1):52. doi: 10.1186/s12974-018-1087-7.
3
Role of NK1 and NK2 receptors in mouse gastric mechanical activity.
NK1和NK2受体在小鼠胃机械活动中的作用。
Br J Pharmacol. 2006 Feb;147(4):430-6. doi: 10.1038/sj.bjp.0706645.
4
Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain.神经激肽NK1和NK3受体作为治疗胃肠动力障碍和疼痛药物的靶点。
Br J Pharmacol. 2004 Apr;141(8):1303-12. doi: 10.1038/sj.bjp.0705742. Epub 2004 Mar 15.
5
Nausea and emesis: still an unsolved problem in cancer patients?恶心与呕吐:癌症患者中仍未解决的问题?
Support Care Cancer. 2002 Mar;10(2):85-7. doi: 10.1007/s00520-001-0339-7. Epub 2002 Jan 31.